Skip to main content

Advertisement

SpringerLink
Log in

Histology-Driven Chemotherapy in Soft Tissue Sarcomas

  • Soft Tissue Sarcomas
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Doxorubicin and ifosfamide are the two chemotherapy drugs that have consistently demonstrated activity in “soft tissue sarcoma” (STS). However, STS is not a homogeneous entity but an umbrella term for a diverse group of more than 40 differing subtypes; each with distinct underlying biology, natural history and response to treatments. The accuracy of the histological and in some cases molecular diagnosis is therefore critical to the optimal treatment of these patients. Leiomyosarcomas have been shown to have limited responsiveness to ifosfamide, but both the combination of gemcitabine and docetaxel, and single agent trabectedin have shown considerable activity in this tumour group. Differences in responses to chemotherapy are seen for leiomyosarcomas of different anatomical sites with uterine leiomyosarcoma demonstrating considerable chemo-responsiveness, whereas vascular leiomyosarcomas appearing far less sensitivity. There is considerable variation in the sensitivity of the three main subtypes of liposarcomas, with well-differentiated liposarcomas showing generalised chemo-resistance through to the impressive responses seen anthracyclines and to trabectedin with the myxoid subtype. Angiosarcomas have demonstrated considerable sensitivity to paclitaxel, a drug that has little activity outside of vascular sarcomas, and liposomal doxorubicin appears to have a particular indication in this subtype. Synovial sarcomas appear to have significant sensitivity to ifosfamide, even on re-challenge. On the other hand, there are subtypes that are chemo-resistant, including gastrointestinal stromal tumour, alveolar soft part sarcoma and clear cell sarcoma, and chemotherapy plays no role in their management. Whilst it is obvious that there is a need to find new agents to treat these tumours, there is an imperative to make sure that the studies that evaluate their “efficacy” are designed to determine the efficacy within differing histiotypes through stratification by histological subtype, or enrichment strategies to ensure that “activity” is not diluted by unresponsive or even chemo-resistant tumour types.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance•• Of major importance

  1. Sleijfer S, Seynaeve C, Verweij J. Using single agent therapy in adult patients with advanced soft tissue sarcomas can still be considered standard. Oncologist 2005, 10: 833–841.

    Article  CAS  PubMed  Google Scholar 

  2. Judson I, Radford J, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001; 37: 870–877

    Article  CAS  PubMed  Google Scholar 

  3. Van Glabbeke M, Van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2185 patients treated with anthracycline-containing first-line regimens—a European Organization for the Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999, 17: 150–157.

    PubMed  Google Scholar 

  4. Tascilar M, Loos WJ, Seynaeve C, et al. The pharmacological basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. The Oncologist 2007, 12: 1351–1360

    Article  CAS  PubMed  Google Scholar 

  5. Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 2010;46:72–83.

    Article  CAS  PubMed  Google Scholar 

  6. Svancárová L, Blay JY, Judson IR, et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002, 38:556–559.

    Article  PubMed  Google Scholar 

  7. Okuno S, Ryan LM, Edmonson JH, et al. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 2003, 15: 1696–1673.

    Google Scholar 

  8. Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001, 19: 3483–3489.

    CAS  PubMed  Google Scholar 

  9. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991, 9: 491–498.

    CAS  PubMed  Google Scholar 

  10. Ferraresi V, Ciccarese M, Cercato MC, et al. Gemcitabine at fixed dose-rate in patients with advanced soft tissue sarcomas: a mono-institutional phase II study. Cancer Chemother Pharmacol 2008, 63:149–155

    Article  CAS  PubMed  Google Scholar 

  11. Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults; a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 2000; 18: 2081–2086.

    CAS  PubMed  Google Scholar 

  12. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002, 20:2824–2831.

    Article  CAS  PubMed  Google Scholar 

  13. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25:2755–2763.

    Article  CAS  PubMed  Google Scholar 

  14. Hensley ML, Blessing JA, Mannel R, et al. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008,109:329–334.

    Article  CAS  PubMed  Google Scholar 

  15. Hensley ML, Blessing JA, Degeest K, et al. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2008, 109:323–328.

    Article  CAS  PubMed  Google Scholar 

  16. Hensley ML, Ishill N, Soslow R, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I–IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol 2009, 112; 563–567.

    Article  CAS  PubMed  Google Scholar 

  17. Van Glabbeke M, Verweij J, Judson I, et al. Progression-free rate as the principal end-point for phase II trials in soft tissue sarcomas. Eur J Cancer 2002, 38: 543–549.

    Article  PubMed  Google Scholar 

  18. Carbonero R, Supko J, Maki R, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicentre phase II and pharmacokinetic study. J Clin Oncol 2005, 23: 5484–5492.

    Article  Google Scholar 

  19. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation of the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. J Clin Oncol 2005, 23: 576–584.

    Article  PubMed  Google Scholar 

  20. Demetri GD, Chawla SP, von Mehren M, et al: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009, 27:4188–4196

    Article  CAS  PubMed  Google Scholar 

  21. Coindre JM, Pedeutour F, Aurias A et al. Well-differentiated and dedifferentiated liposarcoma. Virchows Arch 2010, 456: 167–179.

    Article  CAS  PubMed  Google Scholar 

  22. Orvieto E, Furlanetto A, Laurino L, et al: Myxoid and round cell liposarcoma: a spectrum of myxoid adipocytic neoplasia. Semin Diagn Pathol 2001, 18: 267–273

    CAS  PubMed  Google Scholar 

  23. Jones RL, Fisher C, Al-Muderis O, et al. Differential sensitivity of liposarcoma subtypes to chemotherapy, Eur J Cancer 2005,41:2853–2860.

    Article  CAS  PubMed  Google Scholar 

  24. Patel SR, Burgess M, Plager C, et al. Myxoid liposarcoma. Experience with chemotherapy. Cancer 1994; 74: 1265–1269.

    Article  CAS  PubMed  Google Scholar 

  25. Grosso F, Jones RL, Demetri GD, et al: Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007, 8:595–602.

    Article  CAS  PubMed  Google Scholar 

  26. Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcoma (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009, 20: 1439–1444.

    Article  CAS  PubMed  Google Scholar 

  27. Fata F, O’Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999, 86; 2034–2037.

    Article  CAS  PubMed  Google Scholar 

  28. Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behaviour depending on primary site: a retrospective study of 161 cases. Ann Oncol 2007, 18: 2030–2036

    Article  CAS  PubMed  Google Scholar 

  29. Fury MG, Antonescu CR, Van Zee KJ, et al. A 14 year retrospective review of angiosarcoma: clinical characteristics, prognostic factors and treatment outcomes with surgery and chermotherapy. Cancer J 2005; 11: 241–247

    Article  PubMed  Google Scholar 

  30. Schlemmer M, Reichardt P, Verweij J, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2008, 44: 2433–2436

    Article  CAS  PubMed  Google Scholar 

  31. Van Dalen EC, Michiels EM, Caron HN et al. Different anthracycline derivatives for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010, ; (3) CD005006

  32. Charrois GJ, Allen TM. Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther 2003, 306: 1058–1067.

    Article  CAS  PubMed  Google Scholar 

  33. Krown SE, Northfelt DW, Osoba D et al. Use of liposomal anthracyclines in Kaposi’s sarcoma. Semin Oncol 2004, 31 (suppl 13): 36–52.

    Article  CAS  PubMed  Google Scholar 

  34. Eiling S, Lischner S, Busch JO, et al. Complete remission of radiation-resistant angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin. Br J Dermatol 2002, 147: 150–153

    Article  CAS  PubMed  Google Scholar 

  35. Wollina U, Füller J, Graefe T, et al. Angiosarcoma of the scalp: treatment with liposomal doxorubicin and radiotherapy. J Cancer Res Clin Oncol 2001, 127:396–399.

    Article  CAS  PubMed  Google Scholar 

  36. Skubitz K, Haddad P. Paclitaxel and liposomal doxorubicin are both active in angiosarcoma. Cancer 2005, 104: 361–366.

    Article  CAS  PubMed  Google Scholar 

  37. Balcerzak SP, Benedetti J, Weiss GR, et al. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A South West Oncology Group Study. Cancer 1995, 76: 2248–2252

    Article  CAS  PubMed  Google Scholar 

  38. Casper ES, Waltzman RJ, Schwartz GK et al. Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest 1998, 16: 442–446

    Article  CAS  PubMed  Google Scholar 

  39. Penel N, Nguyen Bui B, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008, 26; 5269–5274.

    Article  CAS  PubMed  Google Scholar 

  40. Van Hoesel Q, Verweij J, Catimel G, et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. Ann Oncol 1994, 5; 539–542.

    PubMed  Google Scholar 

  41. Spurrell E, Fisher C, Thomas JM, et al. Prognostic factors in advanced synovial sarcomas: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol 2005, 16: 437–444.

    Article  CAS  PubMed  Google Scholar 

  42. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin plus doxorubicin and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993, 11: 1269–1275.

    CAS  PubMed  Google Scholar 

  43. Le Cesne A, Antoine E, Spielmann M, et al. High dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995, 13: 1600–1608.

    PubMed  Google Scholar 

  44. Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 1994, 73: 2506–2511.

    Article  CAS  PubMed  Google Scholar 

  45. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer–Soft tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol. 2009; 27:3126–32.

    Article  CAS  PubMed  Google Scholar 

  46. Penel N, Van Glabbeke M, Marreaud S, et al. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol. 2010; DOI: 10.1093/annonc/mdq608

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sarcoma Unit, Royal Marsden Hospital, Fulham Rd, London, SW3 6JJ, UK

    Michelle Scurr

Authors
  1. Michelle Scurr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michelle Scurr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scurr, M. Histology-Driven Chemotherapy in Soft Tissue Sarcomas. Curr. Treat. Options in Oncol. 12, 32–45 (2011). https://doi.org/10.1007/s11864-011-0140-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-011-0140-x

Keywords

Search

Navigation